Virginia Catalyst and the Commonwealth Health Research Board Awards $300,000 Grant to Study Severe Liver Disease

Virginia Biosciences Health Research Corporation, now known as Virginia Catalyst, and the Commonwealth Health Research Board (CHRB) have partnered to award a $300,000 grant to a team from Sanyal Biotechnology, Eastern Virginia Medical School and George Mason University.

​The grant aims to help accelerate the commercialization of Sanyal Biotechnology’s innovative DIAMONDTM mouse model, which is being commercialized for preclinical assessment of therapeutic agents for non-alcoholic steatohepatitis (NASH), a severe liver disease that can lead to fibrosis, cirrhosis and liver cancer.

Virginia Catalyst will provide $100,000 in funding while CHRB will provide $200,000. Sanyal Biotechnology is investing $166,000 as matching funds for the project titled, “Characterization of GUT Microbiome and Liver Cell Populations to Accelerate Commercialization of the DIAMONDTM Mouse Model.”